Clinical Trial Update: Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing GSK134612 in subjects at increased risk for meningococcal disease versus healthy subjects; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• GSK134612 (Meningococcal vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal | Phase 3 | Status: COMPLETED | Results posted: 2017-10-18